KAUST researchers are working to improve gene editing tools, specifically CRISPR/Cas9, for crop bioengineering to address food security challenges. Magdy Mahfouz's lab is developing a germline engineering platform to produce gene-edited plants without foreign DNA and bypass time-consuming tissue culture. A recent European court decision classifies CRISPR/Cas9 crops as GMOs, facing stringent regulations, contrasting with the U.S. where CRISPR-edited mushrooms are already available. Why it matters: Advances in gene editing at KAUST could significantly enhance crop yields and stress tolerance in the region, but regulatory hurdles remain a key challenge for deployment.
KAUST researchers have developed a CRISPR-Cas system using a heat-stable Cas13 protein (TccCas13a) from Thermoclostridium caenicola, compatible with RT-LAMP for rapid viral detection. The new assay, named OPTIMA-dx, enhances the specificity of RT-LAMP tests by reducing false positives in SARS-CoV-2 detection. The team, led by Dr. Magdy Mahfouz and doctoral student Ahmed Mahas, is transitioning the product to a startup phase for commercialization. Why it matters: This innovation could significantly improve point-of-care diagnostics for COVID-19 and other infections by providing a more accurate and easier-to-use testing method.
A KAUST team developed piRNAi, a gene-silencing tool in nematode worms using synthetic RNA sequences interacting with the piRNA pathway. They successfully silenced genes involved in sex determination and other functions, demonstrating multiplexed gene silencing. The gene silencing lasted for varying durations across generations, up to six generations. Why it matters: This expands the molecular toolkit for gene manipulation and offers potential therapeutic applications in humans, given the presence of the same gene-silencing pathway.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.
Juan Carlos Izpisua Belmonte from the Salk Institute discussed aging and regenerative medicine at the KAUST 2019 Winter Enrichment Program. His team is combining gene editing and stem cell technologies to grow rat organs in mice and human cells in pig and cattle embryos. The Salk team is collaborating with KAUST to rejuvenate organs using noncoding RNAs and small metabolites. Why it matters: This research collaboration between KAUST and the Salk Institute explores innovative approaches to address age-related diseases and organ regeneration, with potential long-term impacts on healthcare in the region.
KAUST and KFSHRC have developed NanoRanger, a new gene sequencing system for identifying mutations causing genetic diseases. NanoRanger offers a faster and simpler process to detect DNA abnormalities at base resolution, building on existing long-read sequencing technologies. The system is designed to be cheaper and faster, targeting diseases prevalent in Saudi Arabia due to consanguinity. Why it matters: The technology has the potential to improve diagnosis and treatment of Mendelian diseases, which are especially prevalent in the Arab world.
KAUST researchers, in collaboration with the Salk Institute and Altos Labs, have identified a class of RNA (LINE-1) that, when compromised, leads to accelerated aging, as seen in progeria. They devised an antisense RNA strategy to block the aberrant function of L1 RNA, reversing the disease in mice and patient-derived cells. Published in Science Translational Medicine, the research suggests that targeting LINE-1 RNA could treat progeroid syndromes and other age-related diseases. Why it matters: This RNA-based approach provides a potential therapeutic avenue for treating premature aging diseases and extending human health span in the region and globally.